Based on prior findings that the C-type lectin MGL can distinguish between the healthy and tumor-derived mucin MUC1 [17] and its immunosuppressive role in T cell immunity [20, 21], we aimed to assess the prognostic value of MGL ligand binding in a series of 386 well characterized stage II and stage III colon cancer patients [23]. The gene discussed is CLEC10A; the disease is malignant colon neoplasm.